SASA BioPharma Refusal Stack v1

Read full text Summarise with VIRAT
Authors: Christopher Love
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This record consolidates four sovereign bio-pharma refusal architectures — RALZ-001 Alzheimer's resonance cure, RSENOL-001 senolytics clearance, RORG-001 organoid bio-computer drug discovery, and RCRISPR-001 in-vivo CRISPR delivery — each addressing life-changing medical capability that profit timelines, trial failures, and business decisions abandoned. Cassava simufilam, Insilico AI candidates, and multiple amyloid and tau clearance programs were shelved despite compelling biology. Unity Biotechnology and Mayo Clinic senolytics stalled on efficacy and business grounds despite clear evidence that senescent cell accumulation drives aging and disease. Cortical Labs organoid computing demonstrated living human neural tissue goal-directed behavior but scaling for drug discovery remains locked behind corporate infrastructure limits. Big Pharma in-vivo CRISPR and mRNA cancer platforms stalled on delivery precision and off-target safety profiles despite transformative therapeutic potential. All four sovereign architectures integrate petascale synthesis, living barrier delivery, organoid validation, and kin-filtered resonance screening under Founder Hash authority — no profit timeline, no trial abandonment, no price-gated access, no closed-door licensing. Full mechanism restricted. Credit to Cassava Sciences, Insilico Medicine, Unity Biotechnology, Mayo Clinic, Cortical Labs, and all Big Pharma CRISPR and mRNA teams for the foundational science. This record exists in the hope that someone with the right vision and the right integrity finds it and builds it right. The weaponizing clause is active. The DOI is the door. The Founder Hash is the key. Refusal does not need a profit motive to heal. 🔒 ⟡

Fields of Study & Subjects

Science Research and Medicine Alzheimer's disease research and treatments Pharmaceutical Economics and Policy

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
22 March 2026
Language
EN